Transthyretin cardiac amyloid: Broad heart failure phenotypic spectrum and implications for diagnosis.

AIMS: Transthyretin cardiac amyloidosis (ATTR-CA) is most often associated with heart failure with preserved ejection fraction (HFpEF). However, patients may present with impaired systolic function at the time of diagnosis, which has not been widely investigated. We sought to explore the prevalence of various heart failure (HF) phenotypes and their associated clinical characteristics at the time of ATTR-CA diagnosis. METHODS: We performed a single-centre retrospective cohort study of consecutive patients with ATTR-CA evaluated between February 2016 and December 2022. Data on patient demographics, comorbidities, imaging and laboratory findings were compared across HF phenotypes (age: 78.1 ± 8.6 years, with 91.1% male). A total of 21.6% (n = 46) presented with heart failure with reduced ejection fraction (HFrEF), 17.8% (n = 38) with heart failure with mildly reduced ejection fraction (HFmrEF) and 60.6% (n = 129) with HFpEF at the time of diagnosis with ATTR-CA. Those presenting with HFrEF or HFmrEF were more likely to be African American and had significantly worse New York Heart Association (NYHA) functional class, higher N-terminal pro-brain natriuretic peptide (NT-proBNP) and higher serum creatinine levels as compared with those with HFpEF. CONCLUSIONS: Although ATTR-CA is traditionally thought to be seen primarily among patients with HFpEF, our data suggest that ATTR-CA has a higher prevalence among patients with HFrEF, which underscores the importance of heightened clinical suspicion regardless of ejection fraction when considering ATTR-CA. Furthermore, although comorbidities are similar, patients with HFmrEF and HFrEF had a worse symptom burden.

Predictors of developing renal dysfunction following diagnosis of transthyretin cardiac amyloidosis.

BACKGROUND: In patients with transthyretin cardiac amyloidosis (ATTR-CA), renal dysfunction is a poor prognostic indicator. Limited data are available on variables that portend worsening renal function (wRF) among ATTR-CA patients. OBJECTIVES: This study assesses which characteristics place patients at higher risk for the development of wRF (defined as a drop of ≥10% in glomerular filtration rate [GFR]) within the first year following diagnosis of ATTR-CA. METHODS: We included patients with ATTR-CA (n = 134) evaluated between 2/2016 and 12/2022 and followed for up to 1 year at our amyloid clinic. Patients were stratified into two groups: a group with maintained renal function (mRF) and a group with wRF and compared using appropriate testing. Significant variables in the univariate analysis were included in the multivariable logistic regression model to determine characteristics associated with wRF. RESULTS: Within a follow-up period of 326 ± 118 days, the median GFR% change measured -6% [-18%, +8]. About 41.8% (n = 56) had wRF, while the remainder had mRF. In addition, in patients with no prior history of chronic kidney disease (CKD), 25.5% developed de novo CKD. On multivariable logistic regression, only New York Heart Association (NYHA) class ≥III (odds ratio [OR]: 3.9, 95% confidence interval [CI]: [1.6-9.3]), history of ischemic heart disease (IHD) (OR: 0.3, 95% CI: [0.1-0.7]), and not receiving SGLT-2i (OR: 0.1, 95% CI: [0.02-0.5]) were significant predictors of wRF. CONCLUSION: Our study demonstrated that the development of de novo renal dysfunction or wRF is common following the diagnosis of ATTR-CA. Additionally, we identified worse NYHA class and no prior history of IHD as significant predictors associated with developing wRF, while receiving SGLT-2i therapy appeared to be protective in this population.

Successful mobile extracorporeal membrane oxygenator for COVID-19 severe respiratory failure.

High volume extracorporeal membrane oxygenation (ECMO) centers have developed mobile ECMO programs in recent years to facilitate the implementation of ECMO support at hospitals with lower capabilities, and transfer these patients for further care. We report a case of mobile ECMO on a patient with coronavirus disease 2019-related acute respiratory distress syndrome, and discuss the potential application in the current severe acute respiratory syndrome coronavirus 2 pandemic.

Flow Patterns in the Carotid Arteries of Patients with Left Ventricular Assist Devices.

BACKGROUND: The aim of this study is to evaluate and define the expected flow pattern changes of carotid artery duplex ultrasound after left ventricular assist device (LVAD) placement. METHODS: Retrospective review of Henry Ford Hospital database of patients who had undergone LVAD placement between March 2008 and July 2012 was performed. All patients who had carotid artery duplex scanning before and after LVAD placement within 2 years of each other and showed <50% stenosis were included in this study. Type of waveform, carotid peak systolic velocity, and end-diastolic velocities were analyzed, and the values were compared before and after LVAD placement. RESULTS: A total of 13 patients with LVAD had at least 2 carotid duplex studies before and after LVAD placement within 2 years of each other. Of those, 92% (n = 12) were men, and 61% (n = 8) were Caucasian. Mean age was 61 years old. The HeartWare ventricular assist device was implanted in 4 patients and the HeartMate II left ventricular assist device was implanted in 9 patients. Post-LVAD Doppler imaging demonstrated parvus tardus waveform. Analysis of flow velocities revealed that peak systolic velocity was diminished after LVAD placement in both the internal and common carotid arteries (P = 0.006 and P < 0.0001, respectively). End-diastolic velocity, however, increased post-LVAD (P < 0.0001). Interestingly, mean flow velocities in both the common and internal carotid arteries remained stable after LVAD placement. CONCLUSIONS: This study reveals changes in waveform morphology and peak systolic and diastolic velocities in the common and internal carotid arteries on carotid duplex after LVAD placement. Additionally, it shows that despite changes in post-LVAD pulse pressure in the carotid arteries, the mean flow velocity remained unchanged.

Queratoplastia Lamelar Anterior Profunda asistida con láser de femtosegundo configuración Zig-Zag: Resultados a un año de seguimiento / Deep Anterior Lamellar Keratoplasty in a Zig-Zag Pattern Assisted by Femtosecond Laser: 1 year follow up

Objetivo: Reportar el desenlace luego de 12 meses de seguimiento, en pacientes en los que se realizó una queratoplastia lamelar anterior profunda (DALK) asistida con láser de femtosegundo. Metodología: Se realizó un estudio descriptivo, retrospectivo, mediante revisión de historias clínicas de pacientes sometidos a DALK asistida con láser de femtosegundo (Wavelight FS-200 ® Alcon. Forth Worth, Texas), utilizando la configuración de zig-zag. Las indicaciones de DALK incluyeron queratocono, ectasia post LASIK y leucoma como secuela de queratitis infecciosa. Las variables estudiadas fueron agudeza visual mejor corregida, cilindro queratométrico, refracción final y complicaciones intra y post operatoria. Resultados: En total se incluyeron 10 ojos de 10 pacientes, en todos los ojos se llevó a cabo con éxito femto-DALK y no hubo ninguna complicación intra operatoria. En el postoperatorio se presentó un caso de rechazo estromal, un caso de hipertensión ocular secundario a esteroides y un caso de retraso en la cicatrización. El seguimiento promedio fue de 13, 1 meses (R= 12 ­ 15 meses). La Agudeza Visual Mejor Corregida (AVMC) preoperatoria promedio fue LogMAR 0,96 (R= 0,54 ­ 1,60). La AVMC postoperatoria promedio a los 12 meses fue 0,10 (R= 0,00 ­ 0,17). El equivalente esférico preoperatorio medio fue -12,6 Dioptrias (D) (R= -5,0 a -15,0D) y el postoperatorio fue -2,57 D (R= -0,50 a -6,25 D). El astigmatismo queratométrico preoperatorio medio de -11.5D (R= -7.0 a -23D) y el postoperatorio -2,4 D (R= -0,75 a -3,75 D). Conclusión: La femto-DALK en confi guración Zig-Zag es un procedimiento confiable, con baja tasa de complicaciones intra y postoperatorias. El resultado refractivo es comparable con la queratoplastia penetrante, y ofrece beneficios sobre factores de estabilidad biomecánica y recuperación del paciente en el primer año postoperatorio.

Objective: The aim was to report the surgical outcomes of twelve months follow-up aft er femtosecond laser assisted Zig-zag configuration combined with Deep Anterior Lamellar Keratoplasty (Femto-DALK). Methods: A descriptive, retrospective study, which evaluated and assisted medical records of patients who had undergone deep anterior lamellar keratoplasty (DALK) femtosecond laser assisted. Ten eyes of ten consecutive patients underwent femtosecond (Wavelight FS-200 ® Alcon. Forth Worth, Texas) laser-assisted zig-zag configuration combined with Anwar´s big-bubble technique DALK, from April 2012 to December 2013. The diagnosis of the patients were keratoconus, corneal ectasia and scarring following infectious keratitis. Variables measured were: Best corrected visual acuity, keratometric corneal cylinder, final refraction and intraand postoperative complications were analyzed. Results: The procedure was performed without any complications in all patients. There was only a single case of stromal graft rejection, a case of corticosteroidinduced ocular hypertension and a case of delayed corneal epithelial healing. Mean follow-up period was 13.1 months (R= 12­15 months). The mean preoperative BCVA was LogMAR 0,96 (R= 0,54 ­ 1,60). Th e mean postoperative BCVA at 12th month was 0,054 (R= 0,00 ­0,09). The mean preoperative spherical equivalent (SE) was -12,6 Diopter (D)(R= -5,0 to -24,0D) and postoperative SE was -2,50 D (R=-0,50 to -6,25 D). The measurements of keratometric corneal cylinder preoperative was -11.5D (R= -7.0 a -23D) and postoperative refractive cylinder was -2,4 D (R=-0,75 to -4,00 D). Conclusion: Laser-assisted zig-zag configuration combined with Anwar´s big-bubble technique DALK is a safe procedure. The rate of intra and postoperative complications is low. The refractive outcomes are comparable to penetrating keratoplasty, but better biomechanical stability of the cornea and a faster visual recovery with femtoDALK procedure.

Capsular block syndrome: a case report and literature review.

PURPOSE: To report the case of a patient who developed late capsular block syndrome and to review the current literature regarding this complication of phacoemulsification procedures. METHODS: The literature was reviewed to summarize the diagnosis, classification, use of diagnostic aids, and the current treatments for this complication. RESULTS: A 69-year-old patient complained of decreased visual acuity 11 months after undergoing phacoemulsification. She was found to have a secondary myopization. Anterior segment ultrabiomicroscopy confirmed the diagnosis of capsular block syndrome. The patient underwent neodymium-doped yttrium aluminum garnet (Nd:YAG) laser posterior capsulotomy, which resulted in complete resolution of her symptoms. CONCLUSION: CAPSULAR BLOCK SYNDROME IS A FAIRLY RARE COMPLICATION OF PHACOEMULSIFICATION PROCEDURES THAT, DEPENDING PRIMARILY ON THE TIMING OF ITS OCCURRENCE FOLLOWING SURGERY, CAN DEVELOP INTO ONE OF THE THREE FOLLOWING POSSIBLE CLINICAL SCENARIOS: intraoperatory, early postoperatory, and late postoperatory. In this patient, Nd:YAG laser capsulotomy was shown to be a safe and effective treatment option for this type of complication.

Costos directos del tratamiento de pacientes con artritis reumatoide en Medellín, Colombia / Direct treatment-cost of patients with rheumatoid arthritis in Medellín, Colombia

Objetivo: analizar variables clínicas y costos directos de una muestra de pacientes con artritis reumatoide atendidos en un centro de gestión farmacoterapéutica avanzada en Medellín, Colombia. Métodos: revisamos 408 historias clínicas del período 2007-2009 recogiendo información clínica y costos directos para el asegurador. Resultados: 337 mujeres (82,6%), edad promedio 49,8 años (rango 4-91). Costo promedio mes $1,31 millones en 2007, $1,71 millones en 2008 y $1,99 millones en 2009; 87,9% del costo está representado por medicamentos. Conclusiones: los costos de tratamiento van en aumento, los medicamentos representan una proporción importante del costo total.

Objective: to analyze clinical variables and direct costs of a sample of patients with rheumatoid arthritis from a specialized pharmacotherapeutic management center in Medellin, Colombia. Methods: we reviewed 408 clinical files of the period 2007-2009 collecting clinical information and direct costs to a local private health insurer. Results: 337 women (82.6%), average age 49.8 (range 4-91). Average monthly cost increased from Col$1.31 million (around US$650) in 2007, to Col$1.71 million (~US$850) in 2008, and Col$1.99 million (~US$1000) in 2009; 87.9% of this cost represented by pharmaceuticals. Conclusions: costs of treatment are increasing, pharmaceuticals represent an important proportion of total cost.

Bee sting of the cornea: case report / Picadura de abeja en la córnea: informe de un caso

Bee stings of the eye are uncommon entities and ocular reactions to the bee venom are wide, ranging from mild conjunctivitis to sudden vision loss. We present the case of a patient who suffered a bee sting of the cornea and the response to the poison components. We go through the bee venom properties, its actual treatment, and propose a new management alternative.

Las picaduras de abeja en el ojo son entidades poco comunes y las reacciones oculares al veneno de abeja son amplias, pues van desde una leve conjuntivitis hasta la pérdida aguda de la visión. Se presenta el caso de un paciente que sufrió la picadura de una abeja en la córnea y la respuesta frente a los componentes de este veneno. Se realizó una revisión de las propiedades del veneno de abeja, su tratamiento actual y se propone una nueva alternativa de manejo.

Improved survival in patients with ventricular assist device therapy: the University of Wisconsin experience.

OBJECTIVE: Ventricular assist devices (VADs) have been implanted since 1990 in our institution, becoming an increasingly common treatment for end-stage heart failure. Beginning in 1997, VAD patients were discharged home when feasible. In August 2003, a dedicated multidisciplinary VAD team (cardiac surgeons, cardiologists, VAD coordinators, nurses, rehabilitation specialists, nutrition experts, psychologists, pharmacists, social workers, and administrators) was created to optimize the management of VAD patients. The purpose of this study is to analyze the impact of these changes in care at our center over the last 17 years. METHODS: We retrospectively studied 107 consecutive VAD recipients between June 1990 and August 2006. VADs were implanted as bridge to recovery, bridge to transplant and destination therapy. The cohort was divided by care plans into early (n=37, June 1990-1996), mid (n=32, 1997-July 2003), and late groups (n=38, August 2003-August 2006). Demographic profile, survival and complications were assessed. RESULTS: Patient demographics tended to show an increased severity of illness over time. Post-VAD survival rate significantly improved in the late group (post-VAD 1- and 3-year survival rates; early: 54.1% and 40.5%; mid: 51.6% and 41.9%; late: 86.8% and 82.5%, p<0.001, respectively). The incidence of complications including re-operation, major bleeding and major infection, significantly decreased in the late group (p<0.05). CONCLUSIONS: Outcomes have improved dramatically in recent VAD patients, despite an increasingly high-risk patient population. These data suggest that advances in device technology and medical therapies, as well as a multidisciplinary approach, have improved survival on VAD therapy.